Wall Street Zen Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to “Strong-Buy”

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Separately, Piper Sandler restated a “neutral” rating and set a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $43.75.

Collegium Pharmaceutical Stock Up 6.0%

NASDAQ COLL opened at $34.93 on Friday. The company has a debt-to-equity ratio of 3.54, a quick ratio of 1.01 and a current ratio of 1.33. The company has a market capitalization of $1.12 billion, a P/E ratio of 33.59 and a beta of 0.68. Collegium Pharmaceutical has a one year low of $23.23 and a one year high of $42.29. The stock has a 50 day moving average price of $30.76 and a 200-day moving average price of $29.66.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts’ consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a net margin of 5.13% and a return on equity of 97.28%. The firm’s revenue was up 22.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.45 earnings per share. As a group, equities analysts predict that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical declared that its Board of Directors has initiated a stock repurchase program on Monday, July 7th that permits the company to repurchase $150.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Activity

In other news, Director John Gordon Freund sold 6,601 shares of the firm’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the completion of the transaction, the director directly owned 70,658 shares in the company, valued at $2,163,547.96. This trade represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.51% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of COLL. CWM LLC increased its position in shares of Collegium Pharmaceutical by 453.9% in the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares in the last quarter. Wealthquest Corp purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at approximately $62,000. Virtus Fund Advisers LLC increased its position in shares of Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 565 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 368.9% in the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after buying an additional 2,169 shares in the last quarter. Finally, Allworth Financial LP increased its position in shares of Collegium Pharmaceutical by 7,401.7% in the second quarter. Allworth Financial LP now owns 4,351 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 4,293 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.